Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELLOMAK
2018-003969-33Phase 2Active
- Sponsor
- Innate Pharma
- Start
- Jan 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of lacutamab, gemcitabine and oxaliplatin in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) (5 cohorts), sponsored by Innate Pharma. Primary endpoint: Objective response rate. Started Jan 2019; status: active.
02
Drugs
lacutamabgemcitabineoxaliplatin
03
Conditions
cutaneous T-cell lymphoma (CTCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2018-003969-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003969-33.